05.29.26 -- Why Isolators Do Not Automatically Ensure Annex 1 Compliance

We showcase the development of high drug load nanocrystal based tablets and prove that nanocrystals can match the pharmacokinetic performance of ASDs while reducing the overall pill burden.

Aside from the level of shear or ‘gentleness,’ a number of other factors help determine which type of blender will work best in certain applications. Explore considerations for blender selections.

Discover 3D screen printing’s potential to revolutionize pharmaceutical manufacturing with scalable, customizable, multi-drug tablets and precise, patient-centric drug release profiles.

Maximized uptime, minimized changeover time, and efficient OEE are key factors that have influenced the acceptance of aseptic blow-fill-seal in the packaging of pharmaceutical liquids.

A high‑risk facility acquisition in Huntsville became a blueprint for revitalizing a modern pharmaceutical campus. See how coordinated action turned a massive shutdown into a renewed manufacturing hub.

Properly trained visual inspectors are crucial for identifying defects in parenteral drugs, safeguarding patient safety and product quality.

Strategic location, strong regulatory oversight, institutional stability, and deep expertise reduce risk, speed approvals, and enable reliable, long-term pharmaceutical development partnerships.

Pharma and biotech developers rely on adaptable fill‑finish capacity to meet evolving market demands, scale products from clinical to commercial, and respond rapidly to public‑health emergencies.

A modern approach to CCI blends smart design, risk‑based strategies, and deterministic testing to safeguard sterile products. Learn how lifecycle thinking and practical sampling plans strengthen quality.

Operational excellence in drug manufacturing relies on a unified culture of integrity and proactive problem-solving. Aligned global teams strengthen the supply chain for reliable patient treatments.

Modern microbiology laboratories are starting to look different from the laboratories of 10 years ago. The work will be similar, yet technology will be advanced. Automation, in particular, is taking center stage.

Review the complexities of developing linkers – chemical moieties which attach a drug payload to an antibody – and considerations when identifying a CRO for ADC research and development.

Find out how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.

Bispecific antibodies (bsAbs) offer transformative therapeutic potential through dual-target engagement, but their complex structure presents significant manufacturing challenges.

Cloud adoption is essential for BioPharma growth, offering scalable tools for faster research. Success requires a risk-based approach to ensure data integrity and GxP compliance during the shift.